{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:29:25Z","timestamp":1789874965452,"version":"4.0.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jaci.2017.03.012","type":"journal-article","created":{"date-parts":[[2017,5,3]],"date-time":"2017-05-03T07:46:10Z","timestamp":1493797570000},"page":"1423-1430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Biologics in patients with skin diseases"],"prefix":"10.1016","volume":"139","author":[{"given":"Myl\u00e8ne S.","family":"Veilleux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.03.012_bib1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/13543784.2016.1187130","article-title":"A revolutionary therapeutic approach for psoriasis: bispecific biological agents","volume":"25","author":"Torres","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaci.2017.03.012_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40257-016-0179-3","article-title":"Novel oral therapies for psoriasis and psoriatic arthritis","volume":"17","author":"Yiu","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2340\/00015555-1931","article-title":"New drugs and treatment targets in psoriasis","volume":"95","author":"Kofoed","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.03.012_bib4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Mechanisms of disease; psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib5","series-title":"BLA supplement: etanercept treatment of pediatric plaque psoriasis","year":"2008"},{"key":"10.1016\/j.jaci.2017.03.012_bib6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1203475416651605","article-title":"The role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2017.03.012_bib7","series-title":"Cosentyx approval history","year":"2016"},{"key":"10.1016\/j.jaci.2017.03.012_bib8","series-title":"Taltz approval history","year":"2016"},{"key":"10.1016\/j.jaci.2017.03.012_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamadermatol.2016.0269","article-title":"Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis analysis of results from 3 randomized phase 3 clinical trials","volume":"152","author":"Armstrong","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis-results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17a in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2017.03.012_bib15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1203475416631328","article-title":"Use of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2017.03.012_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2017.03.012_bib18","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.012_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaci.2015.01.018","article-title":"Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial","volume":"136","author":"Krueger","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.012_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaad.2014.11.028","article-title":"Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis","volume":"72","author":"D'Souza","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib21","series-title":"FDA approves Inflectra, a biosimilar to Remicade","year":"2016"},{"key":"10.1016\/j.jaci.2017.03.012_bib22","series-title":"FDA approves Erelzi, a biosimilar to Enbrel","year":"2016"},{"key":"10.1016\/j.jaci.2017.03.012_bib23","series-title":"FDA approves Amjevita, a biosimilar to Humira","year":"2016"},{"key":"10.1016\/j.jaci.2017.03.012_bib24","first-page":"412","article-title":"Canadian Psoriasis Guidelines Addendum Committee\u20142016 Addendum to the Canadian Guidelines for the Management for Plaque Psoriasis 2009\u2014chapter 15: the future of psoriasis care","volume":"20","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2017.03.012_bib25","article-title":"The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis","author":"Griffiths","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(15)00389-X","article-title":"Dupilumab: a milestone in the treatment of atopic dermatitis","volume":"387","author":"Tsianakas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.03.012_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","article-title":"Cellular and molecular immunologic mechanisms in patients with atopic dermatitis","volume":"138","author":"Werfel","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.012_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2017.03.012_bib30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2017.03.012_bib31","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course\u2014a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaci.2017.03.012_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2500\/aap.2008.29.3160","article-title":"Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study","volume":"29","author":"Sheinkopf","year":"2008","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2017.03.012_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jaci.2007.11.016","article-title":"Anti-CD20 (rituximab) treatment improves atopic eczema","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.012_bib34","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jaci.2008.03.007","article-title":"Anti-CD20 (rituximab) treatment for atopic eczema","volume":"121","author":"Sediva","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.012_bib35","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.jaci.2011.09.009","article-title":"Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection","volume":"128","author":"Navarini","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.03.012_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1104200","article-title":"Mutual antagonism of T cells causing psoriasis and atopic eczema","volume":"365","author":"Eyerich","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-4632.2011.05195.x","article-title":"Treatment of severe refractory adult atopic dermatitis with ustekinumab","volume":"51","author":"Puya","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/jdv.12918","article-title":"Inadequate response to ustekinumab in atopic dermatitis\u2014a report of two patients","volume":"30","author":"Samorano","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2017.03.012_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib40","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaad.2005.03.013","article-title":"Etanercept is minimally effective in 2 children with atopic dermatitis","volume":"53","author":"Buka","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0190-9622(93)70026-P","article-title":"Recombinant interferon gamma therapy for atopic dermatitis","volume":"28","author":"Hanifin","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib42","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.4049\/jimmunol.176.12.7456","article-title":"IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets","volume":"176","author":"Andrews","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2017.03.012_bib43","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib46","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaci.2017.03.012_bib47","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMe1411158","article-title":"Rapid evolution of combination therapy in melanoma","volume":"371","author":"Curti","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib48","series-title":"A new era approaches: anti-ctla-4 monoclonal antibodies for the treatment of malignant melanoma","year":"2009"},{"key":"10.1016\/j.jaci.2017.03.012_bib49","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib50","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib51","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib52","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and combimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib53","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition along in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib54","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jaci.2017.03.012_bib55","article-title":"Pembrolizumab plus ipilimumab for advanced melanoma: results of the KEYNOTE-029 expansion cohort","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2017.03.012_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers8010017","article-title":"Updates in therapy for advanced melanoma","volume":"8","author":"Singh","year":"2016","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaci.2017.03.012_bib57","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40164-016-0054-1","article-title":"Novel melanoma therapy","volume":"5","author":"Hsueh","year":"2016","journal-title":"Exp Hematol Oncol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.03.012_bib58","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","article-title":"Pathophysiology of hidradenitis suppurativa: an update","volume":"73","author":"Prens","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.03.012_bib59","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jaad.2015.07.044","article-title":"Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis","volume":"73","author":"Mehdizadeh","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.03.012_bib60","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2015.07.055","article-title":"Systemic associations of hidradenitis suppurativa","volume":"73","author":"Kohorst","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.03.012_bib61","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jaad.2015.07.049","article-title":"Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa","volume":"73","author":"Alhusayen","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib62","series-title":"AbbVie's HUMIRA\u00ae (Adalimumab) receives first and only U.S. Food and Drug Administration approval for moderate to severe hidradenitis suppurativa","year":"2015"},{"key":"10.1016\/j.jaci.2017.03.012_bib63","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.03.012_bib64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2340\/00015555-1229","article-title":"Management of recalcitrant hidradenitis suppurativa with ustekinumab","volume":"92","author":"Sharon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2017.03.012_bib66","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib67","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2017.03.012_bib68","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jaad.2015.07.053","article-title":"Treatment of hidradenitis suppurativa with biologic medications","volume":"73","author":"Lee","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib69","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib70","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)\u2014a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib71","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2014.01.047","article-title":"Diagnosis and classification of autoimmune blistering diseases","volume":"13","author":"Baum","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.03.012_bib72","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2015.10.051","article-title":"Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission","volume":"74","author":"Daneshpazhooh","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib73","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1684\/ejd.2016.2792","article-title":"Epidemiological data of 290 pemphigus vulgaris patients: a 29-year retrospective study","volume":"26","author":"Baum","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib74","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/jamadermatol.2014.136","article-title":"JAMA Dermatol patient page: pemphigus","volume":"150","author":"Jonkman","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib75","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jaad.2015.11.008","article-title":"Future therapies for pemphigus vulgaris: rituximab and beyond","volume":"74","author":"Huang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib76","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus: an update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib77","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2015.04.038","article-title":"The role of adjuvant therapy in pemphigus: a systematic review and meta-analysis","volume":"73","author":"Atzmony","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib78","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in\u00a0vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.03.012_bib79","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2017.03.012_bib80","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaci.2017.03.012_bib81","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/11535420-000000000-00000","article-title":"B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data","volume":"70","author":"Looney","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2017.03.012_bib82","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1186\/ar4615","article-title":"Adalimumab regulates intracellular TNF\u03b1 production in patients with rheumatoid arthritis","volume":"16","author":"Zamora-Atenza","year":"2014","journal-title":"Arthritis Res Ther"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917305110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917305110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:04:55Z","timestamp":1758791095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917305110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0091674917305110"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.03.012","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologics in patients with skin diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}